Compare
Rigel Pharmaceuticals Inc vs Ardelyx, Inc. vs Standard Biotools Inc. vs Nuvation Bio Inc.
| Latest fiscal year | Rigel Pharmaceuticals Inc RIGLRevenue covers only part of its income (partial revenue) | Ardelyx, Inc. ARDX | Standard Biotools Inc. LAB | Nuvation Bio Inc. NUVB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $407.32M | $85.33M | $62.90M |
| Revenue growth (YoY) | n/a | +22.1% | -6.2% | +699.0% |
| Gross margin | n/a | 90.3% (computed) | 49.9% | n/a |
| Operating margin | n/a | -10.1% | -129.2% | -338.7% |
| Net margin | n/a | -15.1% | -87.8% | -325.3% |
| Net income | $367.02M | -$61.60M | -$74.90M | -$204.63M |
| EPS (Diluted) | $19.48 | -$0.26 | -$0.20 | -$0.60 |
| Operating cash flow | $75.66M | -$42.48M | -$74.34M | -$173.43M |
| Free cash flow | n/a | -$43.98M | -$82.65M | n/a |
| Cash & equivalents | $40.58M | $68.00M | $120.86M | $164.09M |
| Total assets | $513.59M | $501.60M | $567.75M | $594.82M |
| Total liabilities | $122.11M | $334.65M | $143.46M | $289.11M |
| Shareholders' equity | $391.48M | $166.95M | $424.29M | $305.72M |
| Return on year-end equity | 93.8% | -36.9% | -17.7% | -66.9% |
| Shares outstanding | 18.31M | 244.35M | 386.38M | 337.84M |
Revenue, most recent five fiscal years
| Fiscal year | Rigel Pharmaceuticals Inc | Ardelyx, Inc. | Standard Biotools Inc. | Nuvation Bio Inc. |
|---|---|---|---|---|
| Latest | n/a | $407.32M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $62.90M Ended 2025-12-31 |
| 1 year earlier | n/a | $333.62M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $7.87M Ended 2024-12-31 |
| 2 years earlier | n/a | $124.46M Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $52.16M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $10.10M Ended 2021-12-31 | $130.58M Ended 2021-12-31 | n/a |